Status:
TERMINATED
Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)
Lead Sponsor:
Merck Sharp & Dohme LLC
Collaborating Sponsors:
Ariad Pharmaceuticals
Conditions:
Advanced Cancers
Eligibility:
All Genders
1+ years
Phase:
PHASE2
Brief Summary
To describe the long-term safety of deforolimus (ridaforolimus, MK-8669) in participants for whom a clinical benefit has been established in a prior parent trial (MK-8669-013, NCT00060645; MK-8669-016...
Eligibility Criteria
Inclusion
- Must have participated on a deforolimus (ridaforolimus) parent trial
- Must have derived a clinical benefit from the parent trial
- Is not on any other anti-cancer treatment(s) unless the therapy was allowed on the parent protocol
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 if the participant is scheduled to receive treatment with deforolimus; no requirement if the participant is included for follow-up purposes only
- Participant of childbearing potential must have a negative pregnancy test within 7 days prior to screening and must use approved contraceptive from screening until 30 days after the last dose of study drug
- Signed informed consent
Exclusion
- Has not participated on a parent trial
- Women who are to receive study drug who are pregnant or lactating
- Any condition in the Investigator's judgment that renders the participant unable to fully understand and provide informed consent and/or comply with the protocol
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2018
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT00836927
Start Date
February 1 2009
End Date
February 4 2018
Last Update
February 18 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.